GEN2X的动态

?? A new in vivo model for Melanoma ?? Get access to a novel ectopic/orthotopic model that recapitulates genetic drivers found in a significant proportion of human melanoma: ?? YUMM1.7 ?? This syngeneic model is now available for evaluating your new therapies. Learn more information here: https://buff.ly/3WZqGoq #melanoma #oncology #research #model #preclinical "immunooncology

We’re working to stop the proliferation of malignant cancer cells in both blood cancers and solid tumours. ? Watch this short animation to learn about the potential of our unique and highly selective inhibitor, dencatistat, to address these high unmet medical needs. ? ? #CTPS1 #oncology #biotech #drugdiscovery

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/4cRuptj #oncology #hematology #biotech #ClinicalTrials #diversity

?? Gain Clarity on Your patient's Breast #Cancer Journey with #siParadigm's PROSIGNA. ??Prosigna is a second-generation genomic test that utilizes the renowned PAM50 gene signature to identify the intrinsic subtype of your patients' breast cancer. Visit www.siparadigm.com today to discover more about how Prosigna #oncology #innovation

We heard you on a need for Decentralized + Comprehensive Genomic Profiling Liquid Biopsy and we are pleased to share that now we have developed a curated panel of 152 genes deemed important by oncologists/ pathologists. Watch this insightful video to learn more about this groundbreaking assay, or click here to discover more: https://lnkd.in/gy6aYpGV #LiquidBiopsy #NGS #Oncology #PrecisionMedicine #AmoyDx #CancerDiagnostics

Defining equitable factors that influence the use of NGS testing across diverse solid tumour indications can be challenging. However, the benefits of comprehensive genomic testing cannot be overstated. The American Society of Clinical Oncology Provisional Clinical Opinion highlights its potential to revolutionize cancer treatment. With six tumor-agnostic therapies/regimens already approved in the United States and more currently under evaluation, patients can benefit greatly from NGS testing. But what are the actual benefits for patients? Stay tuned for more insights on this topic. Follow the link to download the full article: https://lnkd.in/gCGUDSbM Are you interested in learning more about precision oncology and trial matching? Check out our hashtags #NGStesting #oncology #genomictesting #precisiononcology #trialmatching #trialrecommender #AIinPrecisionOncology #fromthewetlabtotheclinic for more information.

Journey through a patient's mCRPC treatment program with urologist Neal Shore. ??https://ow.ly/rTCX50QABXL Updated with recent data, in this animated video you'll hear about the importance of genetic testing when treating prostate cancer with PARP inhibitor monotherapy. The video is designed to make learning simple and engaging. You will learn about: > Efficacy and safety profiles of PARP inhibitors for prostate cancer > The role of genetic testing and how to use it to assess HRRm status and influence treatment decision-making > Data from key PARPi mCRPC studies and the clinical implication of this data ZERO Prostate Cancer?endorsed #MedEd?#MedicalEducation?#Oncology?#ProstateCancer

In this case study video, Dr Andrew Armstrong takes us through the treatment of a patient with metastatic castration-resistant prostate cancer. ?? https://ow.ly/JW9850QeX14 How should we treat this patient using PARP inhibitors in combination with non-hormonal agents? Dr Armstrong guides us through this patient's germline and somatic genetic assessment and how the outcome impacts our choice of therapy. We are led through the latest trial data regarding the efficacy and side-effects of PARP inhibitors and how to use this information to guide our treatment choices. This program is endorsed by?ZERO Prostate Cancer?and NASPCC #MedEd?#ProstateCancer?#MedicalEducation?#Oncology

?? In this exclusive interview from UROonco24, Dr. Juan Gómez Rivas and Dr. Ursula Vogl discuss advancements in genomic profiling and the use of PARP inhibitors in treating metastatic prostate cancer, with a focus on genomic profiling, patient selection and toxicity management. Dr. Vogl highlights the importance of testing both somatic and germline mutations to ensure patients receive the best treatment. She shares her expert opinion on PARP inhibitors and how to manage toxicities with careful monitoring and adjustments, stressing the need for personalised treatment approaches. ?? #prostatecancer #oncology

At this year’s #ENASymp24, Léa Sta, PhD presented our latest research in a poster titled “Data analysis and model evaluation of chemotherapy-induced neutropenia – results from the PARTNER trial.” ?? Our team at Physiomics plc has developed a precision dosing tool which aims to reduce toxicity for patients treated with docetaxel. The PARTNER trial provided valuable clinical data from prostate cancer patients treated with docetaxel to help validate this tool and confirm its ability to predict levels and timing of episodes of neutropenia associated with docetaxel use. We’re excited to share this work with you and invite you to explore the full poster. Click below to learn more about our findings ?? https://lnkd.in/e4a-n3dJ #PKPD #Oncology #ClinicalTrials #Neutropenia #PrecisionDosing